ResMed said net revenue for the 3 months ended March 31, 2025 was $1,291.7 million, an increase of 8% compared to $1,197.0 million for the prior-year period (a 9% increase on a constant currency basis). The company attributed the increase in devices and masks to increased demand and unit sales.

1. 01

   ResMed said net revenue for the 3 months ended March 31, 2025 was $1,291.7 million, an increase of 8% compared to $1,197.0 million for the prior-year period (a 9% increase on a constant currency basis). The company attributed the increase in devices and masks to increased demand and unit sales.

2. 02

   ResMed said gross profit for the 3 months ended March 31, 2025 was $766.4 million and gross margin was 59.3%, compared to 57.9% for the prior-year period. The company cited manufacturing and logistics efficiencies, component cost improvements and favorable product mix as factors, partially offset by unfavorable foreign currency movements.

3. 03

   ResMed said net income for the 3 months ended March 31, 2025 was $365.0 million, an increase of 21% compared to $300.5 million for the prior-year period, and diluted earnings per share was $2.48 compared to $2.04 for the prior-year period. The effective tax rate for the period was 12.6%.

4. 04

   ResMed said cash flow from operating activities for the 9 months ended March 31, 2025 was $1,212.8 million compared to $961.1 million for the prior-year period, and included $107.0 million of tax refunds and related interest and penalties. During the 9 months, the company repurchased $200.0 million of treasury stock.

Key figures

Quarter ended March 31, 2025

Revenue

$1.3B

Operating income

$426M

Net income

$365M

EPS

$2.48

Gross profit

$766M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.